Protocol for the examination of specimens from patients with melanoma of the skin

Archives of Pathology and Laboratory Medicine

Volumn 127, Issue 10, 2003, Pages 1253-1262

  Compton, Carolyn C ^a   Barnhill, Raymond ^b   Wick, Mark R ^c   Balch, Charles ^d  

^a MCGILL UNIVERSITY   (Canada)

^b GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^d AMERICAN SOCIETY OF CLINICAL ONCOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER CLASSIFICATION; CANCER GROWTH; CANCER INVASION; CANCER REGRESSION; CANCER STAGING; EVALUATION; HUMAN; MEDICAL DOCUMENTATION; MELANOMA; METASTASIS; PRACTICE GUIDELINE; REVIEW; TUMOR ASSOCIATED LEUKOCYTE;

BIOPSY; CLINICAL PROTOCOLS; FEMALE; HUMANS; MALE; MELANOMA; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM STAGING; SKIN; SKIN NEOPLASMS;

EID: 0141891874     PISSN: 00039985     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (42)

1. Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 2001;19:3635-3648.
2. Balch CM. Cutaneous melanoma: prognosis and treatment results worldwide. Semin Surg Oncol. 1992;8:400-414.
3. Thorn M, Ponten F, Bergstrom R, Sparen P, Adami HO. Clinical and histopathologic predictors of survival in patients with malignant melanoma: a population-based study in Sweden. J Natl Cancer Inst. 1994;86:761-769.
4. Buzaid AC, Tinoco LA, Jendiroba D, et al. Prognostic value of size of node metastasis in patients with cutaneous melanoma. J Clin Oncol. 1995;13:2361-2368.
5. Kuehnl-Petzoldt C, Wiebelt H, Berger H. Prognostic groups of patients with stage I melanoma. Arch Dermatol. 1983;119:816-819.
6. Masback A, Westerdahl J, Ingvar C, Olsson H, Jonsson N. Cutaneous malignant melanoma in southern Sweden 1965, 1975, and 1985: prognostic factors and histologic correlations. Cancer. 1997;79:275-283.
7. Averbook BJ, Russo LJ, Mansour EG. A long-term analysis of 620 patients with malignant melanoma at a major referral center. Surgery. 1998;124:746-756.
8. Roses DF, Provet JA, Harris MN, Gumport SL, Dubin N. Prognosis of patients with pathologic stage II cutaneous malignant melanoma. Ann Surg. 1985;201:103-107.
9. Balch CM, Murad TM, Soong SJ Ingalls AL, Halpern NB, Maddox WA. A multifactorial analysis of melanoma: prognostic histopathological features comparing Clark's and Breslow's staging methods. Ann Surg. 1978;188:732-742.
10. Balch CM, Soong SJ, Murad TM, Smith JW, Maddox WA, Durrant JR. A multifactorial analysis of melanoma, IV: prognostic factors in 200 melanoma patients with distant metastases (stage III). J Clin Oncol. 1983;1:126-134.
11. Eton O, Legha SS, Moon TE, et al. Prognostic factors for survival of patients treated systemically for disseminated melanoma. J Clin Oncol. 1998;16:1103-1111.
12. Coit DG, Rogatko A, Brennan MF. Prognostic factors in patients with melanoma metastatic to axillary or inguinal lymph nodes: a multivariate analysis. Ann Surg. 1991;214:627-636.
13. Cascinelli N, Marubini E, Morabito A, Bufalino R. Prognostic factors for stage I melanoma of the skin: a review. Stat Med. 1985;4:265-278.
14. Stidham KR, Johnson JL, Seigler HF Survival superiority of females with malignant melanoma: a multivariate analysis of 6383 patients exploring the significance of gender in prognostic outcome. Arch Surg. 1994;129:1343-1344.
15. Balch CM, Buzaid AC, Atkins MB, et al. A new American Joint Committee on Cancer staging system for cutaneous melanoma. Cancer. 2000;88:1484-1491.
16. Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001;19:3635-3638.
17. Banerjee SS, Harris M. Morphological and immunophenotypic variations in malignant melanoma. Histopathology. 2000;36:387-402.
18. Nakhleh RE, Wick MR, Rocamora A, et al. Morphologic diversity in malignant melanomas. Am J Clin Pathol. 1990;93:731-740.
19. Greene FL, Page DL, Fleming ID, et al, eds. AJCC Cancer Staging Manual. 6th ed. New York: Springer; 2002.
20. Sobin LH, Wittekind C, eds. UICC TNM Classification of Malignant Tumours. 6th ed. New York: Wiley-Liss; 2002.
21. Hermanek P, Hutter RVP, Sobin LH, Wittekind C. Classification of isolated tumor cells and metastasis. Cancer. 1999;86:2668-2673.
22. Schuchter LM. Review of the 2001 AJCC staging system for cutaneous malignant melanoma. Curr Oncol Rep. 2001;3:332-337.
23. Anstey A, McKee P, Jones EW. Desmoplastic malignant melanoma: a clinicopathological study of 25 cases. Br J Dermatol. 1993;129:359-371.
24. Straume O, Akslen LA. Independent prognostic importance of vascular invasion in nodular melanomas. Cancer. 1996;78:1211-1219.
25. Clemente CG, Mihm MC Jr, Bufalino R, Zurrida S, Collini P, Cascinelli N. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer. 1996;77:1303-1310.
26. Busam KJ, Antonescu CR, Marghoob AA, et al. Histologic classification of tumor-infiltrating lymphocytes in primary cutaneous malignant melanoma: a study of interobserver agreement. Am J Clin Pathol. 2001;115:856-860.
27. Clark WH Jr, Elder DE, Guerry DG 4th, et al. A model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst. 1989;81:1893-1904.
28. Ronan SG, Eng AM, Briele I-IA, et al. Thin malignant melanomas with regression and metastases. Arch Dermatol. 1987;123:1326-1330.
29. Barnhill RL, Fine JA, Roush GC, Berwick M. Predicting five-year outcome for patients with cutaneous melanoma in a population-based study. Cancer. 1996;78:427-432.
30. McMasters KM, Reintgen DS, Ross Mi, et al. Sentinel lymph node biopsy melanoma: controversy despite widespread agreement. J Clin Oncol. 2001;19:2851-2855.
31. Bedrosian I, Faries M, Guerry D 4th, et al. Incidence of sentinel node metastasis in patients with thin primary melanoma (< or = 1 mm) with vertical growth phase. Ann Surg Oncol. 2000;7:262-267.
32. Aitchison TC, Sirel JM, Watt DC, MacKie RM. Prognostic trees to aid prognosis in patients with cutaneous malignant melanoma. Scottish Melanoma Group. Br Med J. 1995;311:1536-1541.
33. Balch CM, Soong SJ, Murad TM, Ingalls AL, Maddox WA. A multifactorial analysis of melanoma, II: prognostic factors in patients with stage I (localized) melanoma. Surgery. 1979;86:343-351.
34. Balch CM, Soong SJ, Murad TM, Ingalls AL, Maddox WA. A multifactorial analysis of melanoma, III: prognostic factors in melanoma patients with lymph node metastases (stage II). Ann Surg. 1981;193:377-388.
35. Buzaid AC, Ross MI, Balch CM, et al. Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of a new staging system. J Clin Oncol. 1997;15:1039-1051.
36. Clark WH Jr, Ainsworth AM, Bernardino EA, et al. Histogenesis and biologic behavior of primary human malignant melanoma of the skin. Cancer Res, 1969;29:705-727.
37. Clark WH JR, Elder DE, Guerry D IV. Dysplastic nevi and malignant melanoma. In: Farmer ER, Hood AF, eds. Pathology of the Skin. Norwalk, Conn: Appleton & Lange; 1990:684-756.
38. Drzewiecki KI, Andersson A. Local melanoma recurrences in the scar after limited surgery for primary tumor. World J Surg. 1995;19:346-349.
39. Elder DE, Guerry D 4th, Epstein MN, et al. Invasive malignant melanomas lacking competence for metastasis. Am J Dermatopathol. 1983;6(suppl):55-61.
40. Reed RJ. The histologic variance of malignant melanoma; the interrelationship of histological subtype, neoplastic progression, and biological behavior. Pathology. 1985;17:301-312.
41. Sirott MN, Bajorin DF, Wong, et al. Prognostic factors in patients with metastatic malignant melanoma: a multivariate analysis. Cancer. 1993;72:3091-3098.
42. Whooley BP, Wallack MK. Surgical management of melanoma. Surg Oncol. 1995;4:187-195.